Clinical trials: Melanoma Stage Iv
Metastatic Melanoma
A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
The purpose of this study is to determine if the combination of everolimus and imatinib will slow the growth of or cause a reduction in the size of the cancer, and to determine the side effects of the combination in patients with…
- Trial name
- NCT00402662
- Testing
- everolimus, Imatinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Metastatic Melanoma
Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
The purpose of this study, is to evaluate Circulating Melanoma Cell (CMC) changes in Metastatic Melanoma (MM) patients, undergoing treatment with selective inhibitors of mutated BRAF.
- Trial name
- CMCBRAF (NCT01878396)
- Testing
- Anti-B-RAF
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Acral Lentiginous Malignant Melanoma, Recurrent Melanoma
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
- Conditions
- Acral Lentiginous Malignant Melanoma, Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma
- Trial name
- NCT00470470
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer, Metastatic Melanoma
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
- Conditions
- Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT02857270
- Testing
- LY3214996, Midazolam, Abemaciclib
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Unresecable Stage IIIc or IV Melanoma
Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK
The therapeutic arsenal of metastatic melanoma has changed considerably over the past 10 years. The treatment of metastatic melanoma is now based on immunotherapy and targeted therapies, while the place of conventional…
- Trial name
- SVALMEL (NCT03553329)
- Testing
- dabrafenib
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Poitiers University Hospital
Melanoma
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Treatment of subjects who have metastatic melanoma that expresses an activated mutant form of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib, and the Cytotoxic T Lymphocyte Antigen 4…
- Trial name
- NCT01400451
- Testing
- Ipilimumab (BMS-734016), Vemurafenib
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Bristol-Myers Squibb
Melanoma Stage III or IV
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have…
- Trial name
- NCT00243594
- Testing
- Peptide-pulsed dendritic cells
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Melanoma (Skin)
Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005537
- Testing
- aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide
- Sponsor
- Fred Hutchinson Cancer Center
Melanoma
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for patients with stage IV melanoma.
- Trial name
- NCT03241927
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nina Bhardwaj
Stage IV Melanoma, Stage III Melanoma
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have high-risk stage III or completely…
- Conditions
- Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
- Trial name
- NCT00019890
- Testing
- dendritic cell-gp100-MART-1 antigen vaccine, sargramostim
- Sponsor
- National Cancer Institute (NCI)
Melanoma
A Phase I/II Study of Sunitinib and Dacarbazine
This is a combination Phase I/II design that explores the toxicity and activity of Sunitinib and Dacarbazine (DTIC) for metastatic melanoma.
- Trial name
- NCT00496223
- Testing
- Sunitinib, Dacarbazine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Melanoma
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
This is a research study to evaluate treatment of metastatic melanoma patients with a combination of drugs. The combination being studied is vemurafenib (also known as Zelboraf®) and High Dose Interleukin-2 (abbreviated as HD…
- Trial name
- PROCLIVITY01 (NCT01683188)
- Testing
- vemurafenib + HD IL-2
- Where
- 21 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clinigen, Inc.
Melanoma
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
This is open label, single arm study for pts with stage IIIB-IV melanoma, accordingly with AJCC staging criteria (8th ed.), with potentially resectable disease.
- Trial name
- NCT06566391
- Testing
- Ipilimumab
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- European Institute of Oncology
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
This phase Ib trial tests the safety, side effects, and best dose of STI-3031 given directly into the into the lymph nodes or the lymph vessels (intra-lymphatic) using the Sofusa DoseConnect device in treating patients with…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma, Recurrent Metastatic Melanoma
- Trial name
- NCT05393713
- Testing
- Anti-PD-L1 Monoclonal Antibody IMC-001, Punch Biopsy
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Metastatic Melanoma
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.
- Trial name
- PROCLIVITY02 (NCT01856023)
- Testing
- High Dose Interleukin-2, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- Clinigen, Inc.
Malignant Melanoma, Metastatic
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
The study is an open-label, single arm single Center Phase II study to evaluate the safety and efficacy of the combination of Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF, Leukine) and Ipilimumab (Yervoy) as therapy…
- Trial name
- GIPI (NCT01363206)
- Testing
- Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Lynn E. Spitler, MD
Stage III/IV Melanoma
A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma
The study aims to evaluate the 6 month-treatment tolerance defined as the immune related grade 3-4 adverse event-free survival of the combination therapy IT ipilimumab + IV nivolumab.
- Trial name
- NIVIPIT (NCT02857569)
- Testing
- Ipilimumab IT, Ipilimumab IV, Nivolumab IV
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Melanoma
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Background: Cell therapy is an experimental cancer therapy. It takes young tumor infiltrating lymphocytes (Young TIL) cells from a person s tumors and grows them in a lab. Then they are returned to the person.
- Trial name
- NCT02621021
- Testing
- young TIL, Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Melanoma
Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma
A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to evaluate the effect of…
- Trial name
- NCT00701987
- Testing
- ALS-357
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Advanced Life Sciences, Inc.